Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system

Journal of Psychiatric Practice

Volumn 14, Issue 6, 2008, Pages 368-378

  Preskorn, Sheldon H ^a,c   Nichols, Alice I ^b   Paul, Jeffrey ^b   Patroneva, Albena L ^b   Helzner, Eileen C ^b   Guico Pabia, Christine J ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b PFIZER INC   (United States)

^c University of Montreal   (United States)

Author keywords

Antidepressants; CYP2D6; Cytochrome P450 (CYP 450) enzymes; Desvenlafaxine; Drug drug interactions; Metabolism; Pharmacokinetics; Venlafaxine

Indexed keywords

2 HYDROXYDESIPRAMINE; CYTOCHROME P450 2D6; DESIPRAMINE; DESVENLAFAXINE; DULOXETINE; PAROXETINE; VENLAFAXINE; ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; O-DESMETHYLVENLAFAXINE; THIOPHENE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT;

AREA UNDER THE CURVE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME SUBSTRATE; HUMAN; MAJOR DEPRESSION; REVIEW; SINGLE DRUG DOSE; BLOOD; DOSE RESPONSE; DRUG EFFECT; ENZYMOLOGY; HEALTH STATUS; METABOLISM;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CYCLOHEXANOLS; CYTOCHROME P-450 CYP2D6; DEPRESSIVE DISORDER, MAJOR; DESIPRAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEALTH STATUS; HUMANS; PAROXETINE; THIOPHENES;

EID: 65849379466     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000341891.43501.6b     Document Type: Review

References (50)

1. Preskorn SH. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (part I). J Psychiatr Pract 2003;9:150-8.
2. Gonzalez FJ, Skoda RC, Kimura S, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988;331:442-6.
3. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: The past, present and future. Trends Pharmacol Sci 2004;25:193-200.
4. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004;369: 23-37.
5. Preskorn SH, Flockhart D. 2006 guide to psychiatric drug interactions. Prim Psychiatry 2006;13:35-64.
6. Preskorn SH, Flockhart D. 2004 guide to psychiatric drug interactions. Prim Psychiatry 2004;11:39-60.
7. Preskorn SH, Alderman J, Chung M, et al. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994;14:90-8.
8. Preskorn SH, Greenblatt DJ, Flockhart D, et al. Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol 2007;27:28-34.
9. Preskorn S, Werder S. Detrimental antidepressant drug-drug interactions: Are they clinically relevant? Neuropsychopharmacology 2006;31:1605-12.
10. McElroy S, Sachse C, Brockmoller J, et al. CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting. AAPS PharmSci 2000;2:E33.
11. Kirchheiner J, Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta 2007;1770:489-94.
12. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006;57:119-37.
13. de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006;47: 75-85.
14. Gaedigk A, Bradford LD, Marcucci KA, et al. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther 2002;72:76-89.
15. Roh HK, Dahl ML, Johansson I, et al. Debrisoquine and Smephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 1996;6:441-7.
16. Johansson I, Oscarson M, Yue QY, et al. Genetic analysis of the Chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994;46:452-9.
17. Rau T, Wohlleben G, Wuttke H, et al. CYP2D6 genotype: Impact on adverse effects and nonresponse during treatment with antidepressants - a pilot study. Clin Pharmacol Ther 2004;75:386-93.
18. Yin OQ, Wing YK, Cheung Y, et al. Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients. J Clin Psychopharmacol 2006;26:367-72.
19. de Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005; 66:15-27.
20. Laugesen S, Enggaard TP, Pedersen RS, et al. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 2005;77:312-23.
21. Preskorn SH. Drug-drug interactions: proof of relevance (part I). J Psychiatr Pract 2005;11:116-22.
22. Zourkova A, Hadasova E. Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurrence of adverse effects. Gen Physiol Biophys 2003;22:103-13.
23. Hendset M, Haslemo T, Rudberg I, et al. The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs. Pharmacopsychiatry 2006;39:121-7.
24. Lessard E, Yessine MA, Hamelin BA, et al. Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. J Clin Psychopharmacol 2001; 21:175-84.
25. Lessard E, Yessine MA, Hamelin BA, et al. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 1999;9:435-43.
26. Whyte EM, Romkes M, Mulsant BH, et al. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly. Int J Geriatr Psychiatry 2006;21:542-9.
27. Shams ME, Arneth B, Hiemke C, et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 2006;31:493-502.
28. Veefkind AH, Haffmans PM, Hoencamp E. Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit 2000;22: 202-8.
29. Hynninen VV, Olkkola KT, Bertilsson L, et al. Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine. Clin Pharmacol Ther 2008;83: 342-8.
30. Wyeth Pharmaceuticals. Pristiq [package insert]. Available at www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm? fuseaction=Search. Label-Approval, accessed Oct. 20, 2008.
31. Muth EA, Moyer JA, Haskins JT, et al. Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 1991;23:191-9.
32. Parks V, Patat A, Behrle J, et al. Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of ascending single doses of desvenlafaxine (DVS-233 SR) in healthy subjects. Poster presented at the Annual Meeting of The American Society for Clinical Pharmacology and Therapeutics, Orlando, FL, March 2-6, 2005.
33. Behrle JA, Nichols AI, McGrory SB, et al. An open-label, randomized, single-dose, dose-proportionality study of oral doses of a sustained-release formulation of desvenlafaxine succinate in healthy subjects. Poster presented at the Annual Meeting of The American Society for Clinical Pharmacology and Therapeutics; Orlando, FL, March 2-6, 2005.
34. Evaluating the pharmacokinetics of venlafaxine ER and desvenlafaxine SR in healthy subjects (Information available at http://clinicaltrials.gov/ct2/ results?term=NCT00329186).
35. Preskorn S, Patroneva A, Silman H, et al. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol (in press).
36. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003;31:815-32.
37. Huang SM, Temple R, Throckmorton DC, et al. Drug interaction studies: Study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 2007;81:298-304.
38. Stern SL, Cooper TB, Nelson LD, et al. 2-Hydroxydesipramine and desipramine plasma levels: How are they related to antidepressant response? Int Clin Psychopharmacol 1996;11: 219-27.
39. U.S. Food and Drug Administration. Guidance for industry: In vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling. [FDA web site] 1999. (Available at www.fda.gov/Cber/gdlns /metabol.pdf, accessed Oct. 2, 2008).
40. U.S. Food and Drug Administration. Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products - general considerations. Revision 1. [FDA web site] 2003. (Available at www.fda.gov/Cder/guidance/5356fnl.pdf, accessed Oct. 2, 2008).
41. Nichols AI, Fatato P, Shenouda M, et al. The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. J Clin Pharmacol 2008, in press (Information available at http://clinicaltrials.gov/ct2/results?term=NCT00329147).
42. Patroneva A, Connolly SM, Fatato P, et al. An assessment of drug-drug interactions: The effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. [published online ahead of print September 22, 2008]. Drug Metab Dispos. doi: 10.1124 /dmd.108.021527 (Information available at http://clinicaltrials. gov/ct2/results?term=NCT00366652).
43. Alderman J, Preskorn SH, Greenblatt DJ, et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 1997;17:284-91.
44. Charlier C, Broly F, Lhermitte M, et al. Polymorphisms in the CYP 2D6 gene: Association with plasma concentrations of fluoxetine and paroxetine. Ther Drug Monit 2003;25:738-42.
45. Grasmader K, Verwohlt PL, Rietschel M, et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004;60:329-36.
46. Skinner MH, Kuan HY, Pan A, et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther 2003;73:170-7.
47. U.S. Department of Health and Human Services, The Centers for Disease Control and Prevention, National Center for Health Statistics. Health, United States, 2006 with chartbook on trends in the health of Americans (available at: www.cdc.gov/nchs/data/hus/hus06.pdf, accessed Oct. 2, 2008).
48. U.S. Department of Health and Human Services, National Institute of Mental Health. Depression. NIH Publication No. 07-3561. Revised 2007 (available at www.nimh.nih.gov/health /publications /depression/nimhdepression.pdf, accessed Oct. 2, 2008).
49. Silkey B, Preskorn SH, Golbeck A, et al. Complexity of medication use in the Veterans Affairs healthcare system: Part II. Antidepressant use among younger and older outpatients. J Psychiatr Pract 2005;11:16-26.
50. Preskorn SH, Shah R, Neff M, et al. The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: Effects with fluoxetine and paroxetine versus sertraline. J Psychiatr Pract 2007;13:5-12.